Manipal Health Enterprises IPO: Price, GMP, Analysis, Review

Manipal Health Enterprises IPO Details

Manipal Health Enterprises IPO is a Mainboard IPO with an issue size of Rs. 9,275.22 Cr by Manipal Health Enterprises Limited, comprising a combination of fresh issue of 13.56 crore shares (Rs. 8,000 Cr) and offer for sale of 2.16 crore shares (Rs. 1,275.22 Cr).

The Manipal Health Enterprises IPO date of opening is 29 Jul 2026; its initial public offering will end on 31 Jul, IPO allotment on Aug 03, and refund initiation on Aug 04, 2026, and the listing date (expected) might be on Wednesday, Aug 05, 2026, on the BSE and NSE. 

The Manipal Health Enterprises IPO price band is Rs. 560 to Rs. 590.

If you are also looking to apply in this IPO and are confused about whether you should proceed or not, then we have made an analysis in which we will be covering the company’s business, financials, industry trends, valuation, strengths and weaknesses, its current GMP indications, etc that can help you in taking a decision. Keep scrolling.

Manipal Health Enterprises IPO- Company Analysis 

Manipal Health Enterprises is a healthcare service provider that runs a sizable nationwide network of multispecialty clinics, hospitals, and diagnostic facilities. It is a member of the Manipal Group, which was established by T. M. A. Pai. The company provides a variety of healthcare services, such as organ transplants, oncology, cardiology, neurology, orthopaedics, tertiary and quaternary care, and preventative healthcare. Its hospitals are manned by skilled medical personnel and furnished with cutting-edge medical equipment.

Manipal Health is committed to providing high-quality, patient-centered care and increasing healthcare access through partnerships, smart acquisitions, and ongoing investments in digital health and medical infrastructure.

IPO Timetable (Tentative) 

Industry Growth and Health Industry Outlook

The healthcare delivery market is expected to grow at a CAGR of 10-12% between fiscals 2025 and 2030 to Rs 11.2-12.2 trillion. The CAGR for OPD is expected to grow at 8-10% and for IPD at 10.5-12.5%

Click to open demat account and apply for the IPO.

The Objective of the Issue

• Repayment/ prepayment, in full or in part, of certain outstanding borrowings and accrued interest thereon availed by one of the Material Subsidiaries, Manipal Hospitals Private Limited. ~ Rs. 5,552.76 Cr.
• Acquisition of minority stake in the stepdown Subsidiary, Sahyadri Hospitals Private Limited. ~ Rs. 574 Cr.
  
  

Promoters And Management of Manipal Health Enterprises Ltd.

• Ranjan Ramdas Pai
• Manipal Global Health Services
• Memg International Ltd.
• Kangto Investments Pte. Ltd.
• Imperius Healthcare Investments Pte. Ltd.
• Kabru Investments Pte. Ltd.

Hospital Size / Beds (as of 31 March 2026)

Total hospitals: 49 (India)

Licensed beds: 13,037 

Operational beds: ~6,227 

Occupancy: ~64.5%

Region-wise licensed beds:

Company Financials 

• The Total Assets (everything the company owns, such as land, machines, cash, and materials) have shown strong growth over the last three years, driven by acquisitions (e.g., Sahyadri Group), expansion, and investments in PPE, goodwill, and intangibles. As per the Restated Consolidated Financial Information, Total Assets stood at ₹248,645.03 million as at March 31, 2026 (up from ₹140,720.80 million as at March 31, 2025, and ₹108,188.28 million as at March 31, 2024).
  
  

• The Total Income (money earned from main business plus any other income) has shown strong growth. ₹105,205.16 million for FY26 (March 31, 2026), up from ₹83,627.86 million in FY25 and ₹62,651.71 million in FY24. This primarily comprises Revenue from Operations (₹103,357.51 million in FY26).
  
  

• The Profit After Tax (final profit left after paying all costs and taxes) has grown significantly. 9,165.19 million for FY26, compared to ₹10,816.72 million in FY25 and ₹5,332.03 million in FY24. PAT attributable to owners of the Company was ₹8,923.19 million in FY26.
  
  

• The EBITDA (operating profit before deducting interest, taxes, and asset wear-and-tear costs) was approximately ₹27,218.67 million in FY26. EBITDA (excluding exceptional items) was ₹27,959.37 million in FY26 (vs. ₹22,470.70 million in FY25 and ₹17,766.03 million in FY24).
  
  

• The Net Worth (total value belonging to the owners/shareholders of the company) has increased steadily. ₹87,987.63 million as at March 31, 2026 (up from ₹60,001.76 million as at March 31, 2025, and ₹40,875.10 million as at March 31, 2024). This includes Equity Share Capital + Other Equity + Non-controlling Interest.
  
  

• The Reserves (profits saved and kept inside the company for future use)  have increased with retained earnings. ₹81,901.43 million as at March 31, 2026 (up from ₹57,702.81 million as at March 31, 2025, and ₹39,399.05 million as at March 31, 2024), reflecting profits, equity issuances, and other adjustments.
  
  

• The Total Borrowings (total loans and debt taken by the company) have been managed while supporting growth. ₹105,534.31 million as at March 31, 2026 (Non-current: ₹99,488.11 million; Current: ₹6,046.20 million), significantly up due to acquisition-related financing (from lower levels in prior years).
  
  

Financials Snapshot

(Amount in Cr)

Cash Flows

• The Net Cash Flow from Operating Activities (cash generated from the company’s main day-to-day business after adjusting for working capital and taxes) stood at ₹13,886.45 million for the year ended March 31, 2024. It increased to ₹15,698.30 million for the year ended March 31, 2025, and further rose to ₹20,784.01 million for the year ended March 31, 2026.
  
  

• Net Cash Flow from Investing Activities (cash used for buying/selling long-term assets like machinery, property, or investments) was ₹(8,704.95) million for FY24, ₹(26,583.39) million for FY25, and ₹(70,367.42) million for FY26. The sharp increase in outflows in FY26 reflects major acquisitions (e.g., Sahyadri Group).
  
  

• Net Cash Flow from Financing Activities (cash from loans, repayments, share issuance, and interest payments)  was ₹(2,502.09) million for FY24, ₹9,040.82 million for FY25, and ₹49,544.41 million for FY26. The large inflow in FY26 supported growth and acquisitions.
  
  

Cash Flows Snapshot

(Amount in Mn)

Revenue Bifurcation

(Source: RHP)

Region-wise revenue contribution (FY26 Restated):

Karnataka: ~46.4%

Eastern India: ~22.4%

Rest of India: ~19.7%

Maharashtra + Goa: ~11.5%

Listed Peers of Manipal Health Enterprises Ltd. 

Valuation

• The Return on Capital Employed (RoCE), which measures how efficiently the Company generates earnings before interest and taxes from the capital employed, stood at 21.88% for the year ended March 31, 2026.
• The Return on Net Worth (RoNW), which shows the return generated on the shareholders’ funds, was 10.57% for FY 2026.
• The PAT Margin (Profit After Tax Margin), which represents the percentage of revenue that remains as profit after all expenses and taxes, stood at 8.87% for FY 2026.
• The Operating EBITDA Margin, which indicates the operating profitability of the core business before interest, taxes, depreciation and amortisation, was 27.05% for FY 2026. 
  
  

Valuation Snapshot

Is Valuation Expensive?

The valuation appears on the higher side compared to listed peers when looked at on a P/E basis. However, the company has shown strong revenue and EBITDA growth due to multiple acquisitions. Investors would need to evaluate growth prospects, post-acquisition synergies, and margins against this valuation.

Evaluation of P/E Ratio

Considering the period ended FY 2026 with an EPS of Rs. 7.71 from the last year, the resulting P/E ratio is 76.52x.

Explore the Xtranet Technologies IPO.

IPO's Strengths/ Bull Case

• India's largest group of multispecialty hospitals in terms of bed capacity, with a presence throughout the country and leadership in three important regions.
• With leadership in three major cities (Bengaluru, Kolkata, and Pune) and a balanced and varied presence in both metro and non-metropolitan areas, we are the only private hospital chain network in India.
• Patients, physicians, and healthcare professionals choose this well-known brand and network.
  
  

IPO's Weaknesses/ Bear Case

• Dependence on Inpatient Revenue
• Healthcare & Regulatory Risk
• Medical Negligence Risk
  
  

Future Opportunities

• Change in demographics and disease profile.
• Increasing health awareness and rising income levels.
• Rising income levels to make quality healthcare services more affordable.
• Innovations in digital health and telemedicine (enhancing digital healthcare infrastructure).
  
  

Manipal Health Enterprises IPO GMP

Manipal Health Enterprises IPO GMP today is Rs. 33 as of 24 July 2026, while writing this information. With the upper price band of Rs. 590, Manipal Health Enterprises IPO's estimated listing price is Rs. 623. The expected listing gain/loss per share is 5.59%.

Anchor Investors

Details of anchor participation (if any) would be available in filings; pre-IPO investors include entities like Anchorage Capital and Baring PE.

Subscription Status (Live)

Subscription data will be available during/after the issue period on BSE/NSE websites. Check official sources for real-time updates.

Manipal Health Enterprises IPO Lesser Known Facts

• Multiple ED summonses to promoter Dr. Ranjan Ramdas Pai- The Enforcement Directorate sought historical financial and corporate records relating to Dr. Pai and entities in which he previously held an interest. Summonses were issued in 2018, 2019, 2024, 2025 and May 2026 under FEMA-related provisions.
  
  

• Manipal’s investment linked to Medica TS Hospital was impaired by ₹22.23 crore, after which the entire stake was sold to Tata Steel for only about ₹1.49 crore. It also recognised a ₹114.07 crore goodwill impairment relating to HealthMap Diagnostics in FY2024.
  
  

• Customs show-cause notice concerning an aircraft: Customs authorities issued a show-cause notice to Dr. Pai in November 2024 concerning the proposed confiscation of an aircraft and alleged contravention of the Customs Act. The Karnataka High Court stayed further proceedings, while noting that the aircraft did not belong to the petitioners.
  
  

• Manipal Hospital Jaipur linked to an illegal kidney-transplant investigation- An FIR concerning an alleged illegal kidney-transplant racket resulted in a chargesheet against several individuals, including a former doctor and former transplant coordinator of Manipal Hospital Jaipur. The hospital itself was not named in the chargesheet, but it was asked to provide donor, recipient and no-objection-certificate records.
  
  

• ED proceedings under PMLA involving the Jaipur hospital- The ED sought information regarding organ transplants performed at Manipal Hospital Jaipur, doctors and staff involved, payments made to them, bills raised and bank statements. Responses were submitted in 2024 and April 2026, but the RHP describes the matters as pending.
  
  

• Jaipur hospital’s organ-transplant licences were suspended- The RHP states that organ-transplant licences issued by Rajasthan authorities for Manipal Hospital Jaipur had been suspended.
  
  

• Income-tax searches at the company’s offices and hospitals- The Income Tax Department conducted searches between September 7 and September 10, 2022, at the registered office and hospitals on Old Airport Road, Millers Road and Varthur Road. Various assessment orders were subsequently issued.
  
  

• Minority shareholders alleged mismanagement and corporate-governance issues - 
  Certain minority shareholders of Manipal Hospitals Synergie alleged corporate-governance problems, mismanagement and oppression and claimed approximately ₹32.25 crore, including alleged fixed returns on their investment. Complaints were also submitted to SEBI, RBI and the Registrar of Companies. The company denied liability and stated that the alleged promises related to the period before its acquisition.
  
  

• Adverse arbitration award involving a former senior executive- An arbitrator held that former whole-time director and vice-chairman Dr. Sanjeev Bagai had been illegally terminated and awarded him ₹31.02 crore, plus 12% annual interest and costs of about ₹88.8 lakh. Part of the award was later set aside, but the subsidiary deposited approximately ₹22.73 crore with the Delhi High Court, and cross-appeals remained pending.
  
  

• Forty medical-negligence and service-related matters- As of the RHP date, the company and its subsidiaries had 40 pending complaints or notices alleging matters such as medical negligence, service deficiency and misdiagnosis before judicial or regulatory authorities.
  
  

• Large number of proceedings against subsidiaries- The RHP’s litigation summary lists proceedings against subsidiaries comprising:
  
  

• 9 criminal proceedings
  
  

• 180 tax proceedings
  
  

• 30 statutory or regulatory proceedings
  
  

• 3 material civil litigations
  
  

Who Should Avoid this IPO? / Who Should Apply?

Every investor has different risk appetite, financial goals, and analysis methods. The blog suggests reviewing the full RHP, latest GMP, subscription trends, and consulting your own SEBI-registered advisor before making any decision. Allotment is not guaranteed, and market conditions on listing day also matter.

Manipal Health Enterprises IPO Summary

IPO Lot Details 

Manipal Health Enterprises IPO Allotment Status

To check the Manipal Health Enterprises IPO Allotment Status, visit the official Registrar’s website or the BSE website. Below are the website links for you.

Using BSE Website - ​BSE IPO allotment status

IPO Lead Managers

• Kotak Mahindra Capital Co. Ltd.
  
  

Dividend Policy

The company has not paid a Dividend during the last three FYs.

Should You Apply for Manipal Health Enterprises IPO?

Investors are advised to review the full RHP, latest GMP, subscription trends, and consult SEBI-registered professionals before taking any decision. Different investor categories may evaluate scale, valuation, risks, and opportunities differently.

Conclusion

Manipal Health Enterprises IPO offers a chance to invest in one of India’s leading hospital chains with strong revenue growth, robust EBITDA margins, and nationwide presence backed by the reputed Manipal brand. While the company demonstrates healthy operational performance and industry tailwinds, the high valuation, significant OFS component, and various regulatory/litigation matters warrant careful evaluation.

Finowings IPO Analysis

Hope you enjoyed the Finowings IPO Analysis. We tried our best to give every required detail about the company that you should know before applying to the IPO.

You must consult your financial advisor before making any financial decisions.

To Apply for the IPO, Click Here.

To Read the Prospectus of the company, click here to download the DRHP.

Click Here To Stay Updated With The Upcoming IPOs.

DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is purely for educational and informational purposes only. Always consult your eligible financial advisor for investment-related decisions.